Recent Press Releases

Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder

02/16/17 - - Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system thera... More

Neuralstem to Present at BIO CEO & Investor Conference

02/13/17 - GERMANTOWN, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announces tha... More

Neuralstem Announces a 1-for-13 Reverse Stock Split

01/06/17 - GERMANTOWN, Md., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announc... More
More

Upcoming Events


There are currently no events scheduled.
More
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
Share PageShare Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet